To include your compound in the COVID-19 Resource Center, submit it here.

ISV-303: Phase I/II data

Top-line data from a double-blind, U.S. Phase I/II trial in 169 patients undergoing cataract surgery showed that a significantly greater proportion of patients receiving once-daily topical ISV-303 for

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE